Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Audio By Carbonatix

FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct 20, 2025--

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards on (i) October 17, 2025, covering an aggregate of 1,579,500 shares of its common stock, consisting of stock options to purchase an aggregate of 1,553,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 26,500 shares of common stock, to three newly hired employees and (ii) October 20, 2025, covering an aggregate of 1,500,000 shares of its common stock to one newly hired employee, each as an inducement material to their acceptance of employment with Geron.

The stock options granted on October 17, 2025 have an exercise price of $1.20 per share and the stock options granted on October 20, 2025 have an exercise price of $1.27 per share, in each case which is equal to the closing price of Geron common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of each employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. The RSUs granted on October 17, 2025 vest over four years, with 25% of the RSUs vesting on each anniversary of the grant date, subject to continued employment with Geron through the applicable vesting dates.

The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the forms of stock option and RSU agreements under the plan.

About Geron

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other myeloid hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251020724593/en/

CONTACT: [email protected]

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: Geron Corporation

Copyright Business Wire 2025.

PUB: 10/20/2025 05:32 PM/DISC: 10/20/2025 05:33 PM

http://www.businesswire.com/news/home/20251020724593/en